Sign up
Log in
News
VXRT
0.6978
+2.78%
0.0189
Weekly Report: what happened at VXRT last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at VXRT last week (0708-0712)?
Weekly Report · 07/15 09:59
Buy Rating Affirmed for Vaxart Amidst Promising Norovirus Vaccine Developments and Market Opportunity
TipRanks · 07/09 11:25
UPDATE 1-HilleVax to discontinue development of norovirus vaccine for infants; shares plummet
Shares of HilleVax plunged as much as 87.6% to a record low of $1.75 on Monday. Biotech company says it will discontinue development of vaccine candidate for infants. The vaccine, HIL-214, showed an efficacy of only 5% in a mid-stage study of 2,800 infants.
Reuters · 07/08 15:02
Weekly Report: what happened at VXRT last week (0701-0705)?
Weekly Report · 07/08 10:00
Weekly Report: what happened at VXRT last week (0624-0628)?
Weekly Report · 07/01 10:00
Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding
Seeking Alpha · 06/27 12:00
Weekly Report: what happened at VXRT last week (0617-0621)?
Weekly Report · 06/24 10:03
$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. The Dow Jones index closed higher by around 300 points on Thursday. Recent notable insider transactions for penny stocks include Vaxart, Inc. And GlycoMimetics. Clover Health Investments, Corp. Also had a recent notable insider transaction.
Benzinga · 06/21 12:22
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 06/19 16:30
12 Health Care Stocks Moving In Tuesday's Intraday Session
Mustang Bio stock moved upwards by 50.0% to $1.12 during Tuesday's regular session. Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 27.95%. AtriCure shares rose 16.01%. DermTech shares decreased by 59.5%.
Benzinga · 06/18 16:31
Vaxart anticipates funds to extend its cash runway into 2026
Seeking Alpha · 06/18 13:54
Vaxart Provides Corporate Update in Recent Press Release
TipRanks · 06/18 11:31
Vaxart Stock Is Moving Higher After The Bell: What's Going On?
Vaxart Inc (NASDAQ:VXRT) shares are trading higher in Monday's after-hours session. The company provided business and cash runway updates. Vaxart is a biotechnology company developing oral recombinant vaccines. Company says proceeds from a recent offering are expected to extend its cash runway into 2026.
Benzinga · 06/17 20:32
Vaxart Provides Business Update; Expects Net Proceeds From $40M Offering And Reimbursment Under Project NextGen Award Of Up To $453M To Extend Cash Runaway Into 2026
Benzinga · 06/17 20:08
VAXART INC: WELL-CAPITALIZED TO EXECUTE ON MULTIPLE KEY CLINICAL AND REGULATORY MILESTONES IN COVID-19 AND NOROVIRUS PROGRAMS
Reuters · 06/17 20:05
VAXART PROVIDES BUSINESS UPDATE
Reuters · 06/17 20:05
Weekly Report: what happened at VXRT last week (0610-0614)?
Weekly Report · 06/17 10:00
Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
Vaxart, Inc. Shares traded higher in the premarket session on Friday. The company announced a project award worth $453 million for a vaccine candidate. Vaxart also announced an underwritten offering of 50 million shares of its common stock. The stock was up more than 23% at one point.
Benzinga · 06/14 14:06
Health Care Sector Update for 06/14/2024: CABA, VXRT, RARE, XLV, IBB
NASDAQ · 06/14 13:07
More
Webull provides a variety of real-time VXRT stock news. You can receive the latest news about Vaxart Inc through multiple platforms. This information may help you make smarter investment decisions.
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.